- cafead Jul 20, 2023 at 10:02: AM
via Novartis and Roche’s Xolair has had a monopoly on the chronic spontaneous urticaria market for some time, but this is expected to change this year with the approval of Sanofi and Regeneron’s Dupixent for the skin disorder.
And several late-stage projects are due to report clinical data in the next six to 12 months, including BTK inhibitors from Novartis and Sanofi. Amgen, Astrazeneca and the smaller players Allakos and Celldex are all also vying for a piece of the market.
article source
And several late-stage projects are due to report clinical data in the next six to 12 months, including BTK inhibitors from Novartis and Sanofi. Amgen, Astrazeneca and the smaller players Allakos and Celldex are all also vying for a piece of the market.
article source